# Wave Life Sciences, Inc. (WVE)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/wave-life-sciences-inc/ JSON: https://steadybase.io/company/wave-life-sciences-inc.json Checked Nov 10, 2026. Latest filing read: Oct 27, 2026.

## Company

- Legal name: Wave Life Sciences, Inc.
- Ticker: WVE (Nasdaq)
- SEC CIK: 0001631574
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Cambridge, MA
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: wavelifesciences.com
- LinkedIn: https://www.linkedin.com/company/wave-life-sciences
- Next earnings date: Nov 9, 2026

## Key facts

- Revenue: $42.7M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/0001193125-26-073472-index.html
- Operating income: -$215.4M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/0001193125-26-073472-index.html
- Net income: -$204.4M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/0001193125-26-073472-index.html
- SG&A: $75.3M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/0001193125-26-073472-index.html
- Employees: 317 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/wve-20251231.htm
- Shares outstanding: 197,228,968 as of Oct 21, 2026 (10-Q filed Oct 27, 2026). Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526432714/0001193125-26-432714-index.html
- Auditor: Kpmg LLP, Boston, Massachusetts, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/wve-20251231.htm

## Business

We are a clinical-stage biotechnology company focused on unlocking the broad potential of ribonucleic acid (“RNA”) medicines (also known as oligonucleotides), or those targeting RNA, to transform human health. Our RNA medicines platform, PRISM ® , combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and common disorders.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/wve-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $42.7M | -$215.4M | -$204.4M | $75.3M |
| Dec 31, 2024 | $108.3M | -$110.4M | -$97.0M | $59.0M |
| Dec 31, 2023 | $113.3M | -$68.0M | -$57.5M | $51.3M |
| Dec 31, 2022 | $3.6M | -$162.7M | -$161.8M | $50.5M |
| Dec 31, 2021 | $41.0M | -$127.0M | -$122.2M | $46.1M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/wave-life-sciences-inc.json

## Officers and directors

- Paul Bolno, MD, MBA, President and Chief Executive Officer at Wave Life Sciences. Source: 8-K filed Oct 27, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526432690/d120442dex991.htm
- Paul B. Bolno, President and Chief Executive Officer. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/wve-20251231.htm
- Paul B. Bolno, M.D., President, Chief Executive Officer and Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/wve-20251231.htm
- Kyle Moran, Chief Financial Officer. LinkedIn: https://linkedin.com/in/kyle-moran-cfa-2a18288. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/wve-20251231.htm
- Christopher I. Wright, Chief Medical Officer. Source: Form 3 filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526162127/0001193125-26-162127-index.htm
- Erik Ingelsson, Chief Scientific Officer. LinkedIn: https://linkedin.com/in/ingelsson. Source: Form 3 filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526162126/0001193125-26-162126-index.htm
- Chandra Vargeese, Chief Technology Officer , Head of Platform Discovery Sciences. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/wve-20251231.htm
- Christian Henry, Chairman of the Board of Directors. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/wve-20251231.htm
- Christopher Francis, Senior Vice President , Corporate Development, Head of Emerging Areas. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/wve-20251231.htm
- Adrian Rawcliffe, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/wve-20251231.htm
- Aik-Na Tan, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/wve-20251231.htm
- Gregory L. Verdine, Ph.D., Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/wve-20251231.htm
- Heidi L. Wagner, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/wve-20251231.htm
- Ken Takanashi, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/wve-20251231.htm
- Mark H. N. Corrigan, M.D., Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/wve-20251231.htm
- Peter Kolchinsky, Ph.D., Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/wve-20251231.htm
- Chandra Vargeese, Ph.D., Named in proxy. Source: DEF 14A filed Oct 14, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526421806/d162196ddef14a.htm
- Chris Wright, M.D, Ph.D., Named in proxy. Source: DEF 14A filed Oct 14, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526421806/d162196ddef14a.htm
- Christopher Francis, Ph.D., Named in proxy. Source: DEF 14A filed Oct 14, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526421806/d162196ddef14a.htm
- Erik Ingelsson, M.D., Ph.D., Named in proxy. Source: DEF 14A filed Oct 14, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526421806/d162196ddef14a.htm
- Kyle Moran, CFA, Named in proxy. Source: DEF 14A filed Oct 14, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526421806/d162196ddef14a.htm
- Paul B. Bolno, M.D., MBA, Named in proxy. Source: DEF 14A filed Oct 14, 2026, https://www.sec.gov/Archives/edgar/data/1631574/000119312526421806/d162196ddef14a.htm

## Recent 8-K events

- Oct 27, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526432690/d120442d8k.htm
- Jul 30, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526324917/d177737d8k.htm
- Jun 26, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526284002/d70732d8k.htm
- May 18, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526229076/d154261d8k.htm
- Apr 28, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526183563/d135689d8k.htm
- Apr 21, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526167070/d44857d8k.htm
- Apr 15, 2026: Item 1.01, Entry into a material definitive agreement; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526157003/d116643d8k.htm
- Mar 26, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526125092/d17239d8k.htm
- Feb 26, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526073437/d103046d8k.htm
- Feb 2, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526032698/d78838d8k.htm

## Insider trades (Form 4)

- Aug 12, 2026: Adrian Rawcliffe (Director) sold 12,700 shares, about $67,183. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526349962/0001193125-26-349962-index.htm
- Aug 11, 2026: Heidi L. Wagner (Director) sold 7,000 shares, about $42,070. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526349963/0001193125-26-349963-index.htm
- Aug 11, 2026: Ken Takanashi (Director) sold 3,864 shares, about $23,223. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526349961/0001193125-26-349961-index.htm
- Aug 11, 2026: Aik Na Tan (Director) sold 432 shares, about $2,596. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526349960/0001193125-26-349960-index.htm
- Mar 30, 2026: Capital Healthcare Fund LP RA (Director) bought 8,772,496 shares, about $54.6M. Source: https://www.sec.gov/Archives/edgar/data/1631574/000123191926000297/0001231919-26-000297-index.htm
- Mar 30, 2026: Capital Management L.P. Ra (Director) bought 8,772,496 shares, about $54.6M. Source: https://www.sec.gov/Archives/edgar/data/1631574/000123191926000297/0001231919-26-000297-index.htm
- Mar 30, 2026: Peter Kolchinsky (Director) bought 8,772,496 shares, about $54.6M. Source: https://www.sec.gov/Archives/edgar/data/1631574/000123191926000297/0001231919-26-000297-index.htm
- Mar 30, 2026: Rajeev M. Shah (Director) bought 8,772,496 shares, about $54.6M. Source: https://www.sec.gov/Archives/edgar/data/1631574/000123191926000297/0001231919-26-000297-index.htm
- Feb 26, 2026: Chris Francis (See Remarks) sold 33,194 shares, about $499,521. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526083712/0001193125-26-083712-index.htm
- Feb 9, 2026: Kyle Moran (Chief Financial Officer) sold 3,588 shares, about $48,259. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526047323/0001193125-26-047323-index.htm
- Feb 9, 2026: Paul Bolno (President and CEO) sold 10,480 shares, about $140,956. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526047322/0001193125-26-047322-index.htm
- Feb 9, 2026: Chris Francis (See Remarks) sold 1,883 shares, about $25,326. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526047319/0001193125-26-047319-index.htm
- Feb 9, 2026: Chandra Vargeese (See Remarks) sold 3,228 shares, about $43,417. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526047314/0001193125-26-047314-index.htm
- Jan 2, 2026: Chris Francis (See Remarks) sold 9,375 shares, about $150,260. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526005195/0001193125-26-005195-index.htm
- Dec 9, 2025: Kyle Moran (Chief Financial Officer) sold 260,036 shares, about $4.1M. Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312525314736/0001193125-25-314736-index.htm

## What management said

- "We continue to make notable progress advancing our lead clinical programs. Following positive FDA feedback, planning is underway for our potentially registrational trial of WVE-006 for AATD, which we believe offers an efficient path to potential full and accelerated approval, without the need for a separate confirmatory trial. Our growing body of clinical data support WVE-006’s potential to offer a new standard of care for individuals living with AATD" Paul Bolno, MD, MBA, President and Chief Executive Officer at Wave Life Sciences (8-K filed Oct 27, 2026). Source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526432690/d120442dex991.htm

## Latest filings

- 8-K filed Oct 27, 2026: https://www.sec.gov/Archives/edgar/data/1631574/000119312526432690/d120442d8k.htm
- 10-K filed Feb 26, 2026: https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/wve-20251231.htm
- 10-Q filed Oct 27, 2026: https://www.sec.gov/Archives/edgar/data/1631574/000119312526432714/wve-20260930.htm
- DEF 14A filed Oct 14, 2026: https://www.sec.gov/Archives/edgar/data/1631574/000119312526421806/d162196ddef14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/